LOS ANGELES, CA / ACCESSWIRE / June 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Adamas knew it faced serious roadblocks that would inhibit its ability to sell its new drug, Gocovri. The Company failed to disclose these roadblocks as part of its January 2018 Secondary Public Offering ("SPO"), misleading the market. Merrill Lynch released a report in October 2018 casting doubt on the Company's ability to successfully market Gocovri, noting that the Company withheld critical information. Adamas backtracked on its growth estimates in March 2019, refusing to predict the future market share of its new drug. Based on this news, Adamas' share price plunged far below the SPO price.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm
View source version on accesswire.com: